Amylyx Prices Upsized $500M Offering at $35.50 After Avexitide Win

summarizeSummary

Amylyx priced an upsized $500.2 million offering at $35.50 per share, a 43% increase from the initial $350 million plan, to fund the commercial launch of avexitide after positive Phase 3 data.

check_boxKey Events · Financing and Capital Events · AMLX

• Offering Upsized to $500M

  Amylyx priced 14.09 million shares at $35.50 each, raising $500.2 million before fees — up from the $350 million announced on August 18.

• Dilution of ~12.7%

  The offering adds 14.09 million shares to the 111.37 million outstanding, diluting existing holders by approximately 12.7% (or 14.5% if the underwriters' option is fully exercised).

• Net Proceeds $471.7M

  After underwriting discounts of $28.0 million and estimated expenses of $0.5 million, net proceeds are $471.7 million, or $542.5 million with the full option.

• Underwriters and Option

  Leerink Partners, Morgan Stanley, Guggenheim Securities, and LifeSci Capital are joint bookrunners, with a 30-day option for 2,113,500 additional shares.

auto_awesomeAnalysis · AMLX · Life Sciences

Amylyx priced its public offering at $35.50 per share, raising $500.2 million before fees — a 43% increase from the $350 million initially announced two days ago. The deal was upsized on the back of positive Phase 3 LUCIDITY data for avexitide, which sent the stock up 63% to a 52-week high. The offering adds roughly 12.7% to the share count, diluting existing holders, but the capital funds the commercial launch of avexitide if approved. Underwriters Leerink, Morgan Stanley, Guggenheim, and LifeSci Capital have a 30-day option for 2.1 million more shares, which could push total proceeds to $575 million. The pricing at $35.50 versus the August 18 close of $35.11 shows strong institutional demand, but the dilution is real and immediate.